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Abstract
Australia-wide population-based surveillance for scedosporiosis
identiﬁed 180 cases, with 118 (65.6%) cases of colonization and 62
(34.4%) cases of infection. Predisposing factors for isolation of
Scedosporium spp. included chronic lung disease in 37.8% and
malignancy in 21.7% of cases. Predictors of invasive disease
(n = 62) included haematological stem cell transplantation (n = 7),
leukaemia (n = 16) and diabetes mellitus (n = 8). Of 183 phenotyp-
ically-speciated isolates, 75 (41%) were Scedosporium proliﬁcans (risk
factors: haematologic cancer (n = 17), neutropaenia (n = 14)) and
108 (59%) had Scedosporium apiospermum/Pseudallescheria boydii
phenotype [risk factor: diabetes (n = 15)]. Scedosporium proliﬁcans
(p 0.01) and leukaemia (p 0.03) independently predicted death.
Epidemiological and antifungal susceptibility proﬁles of Scedosporium
aurantiacum (prevalence ‡15.8%) and S. apiospermum were similar.
No patient with S. aurantiacum infection (n = 6) died. This is the
ﬁrst description of clinical features associated with S. aurantiacum.
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The epidemiology and optimal treatment of Scedosporium
infections are not well-deﬁned. Scedosporium species cause
25–29% of non-Aspergillus mould infections in organ trans-
plant recipients in the USA and are associated with major
trauma/surgery [1–3]. Additionally, respiratory colonization
has been noted in cystic ﬁbrosis (CF) patients, although the
signiﬁcance of this is uncertain [3–5]. Until recently, Scedos-
porium apiospermum (teleomorph Pseudallescheria boydii) and
Scedosporium proliﬁcans were the only recognized medically-
important species. On the basis of contemporary genetic
analyses, the previously-designated S. apiospermum has been
separated into ﬁve species, collectively comprising the P. boydii
species complex; of these, P. boydii, S. apiospermum and the
new species, Scedosporium aurantiacum, have been found in
clinical specimens [6,7]. During an investigation of genetic
variation amongst Australian Scedosporium isolates (acquired
in 1988–2004), we uncovered a substantial number of S. au-
rantiacum [8].
Because most surveys of scedosporiosis have been limited
to speciﬁc patient populations or single/selected institutions
[9–12], we undertook a 3-year (2003–2005), prospective,
population-based survey encompassing 49 laboratories across
Australia. We sought to identify species-speciﬁc clinical and
laboratory characteristics that might inﬂuence the manage-
ment and outcome of scedosporiosis.
Clinical and microbiological data, including predisposing
factors present within the preceding 90 days [3,9–12], were
recorded. The study was approved by the human ethics
review boards of all the institutions providing clinical data. A
case was deﬁned as the incident isolation of Scedosporium
spp. from any clinical specimen. Invasive scedosporiosis was
deﬁned according to revised European Organisation for
Treatment of Cancer/Mycoses Study Group criteria for
‘proven’/‘probable’ infection [13]. Patients not fulﬁlling these
criteria, including those with ‘possible’ infection, were
considered to be colonized.
Phenotypic methods [14] identiﬁed 183 isolates as S. proliﬁ-
cans or the ‘S. apiospermum/P. boydii phenotype’ (i.e. refers to
P. boydii species complex members). A subset of 120 isolates
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(S. proliﬁcans, n = 49; S. apiospermum/P. boydii, n = 71) were
further categorized as S. aurantiacum, S. apiospermum or
S. proliﬁcans based on polymorphisms in the internal tran-
scribed spacer regions of the rDNA gene [8]; the remaining
63 isolates underwent phenotypic species conﬁrmation [14]
at a reference laboratory. Antifungal susceptibility was deter-
mined by CLSI M38-A methodology [15]. Clinical data were
analysed with STATA, version 9.2 (StataCorp, College Station,
TX, USA). Univariate analyses were performed using a
Student’s t-test or Mann–Whitney U-test (continuous
variables) and chi-square or Fisher’s exact tests (categorical
variables). Independent predictors of association were
identiﬁed by multivariate logistic regression.
Analysis of 180 episodes of scedosporiosis in 180 patients
was performed; 95% of patients were aged >15 years and
57.8% were male. No seasonal variation was noted overall
or by species. At least one co-morbid condition was present
in 140 (77.8%) of cases, most commonly chronic obstructive/
suppurative lung disease [n = 68 (37.8%); CF (13, 7.2%)] fol-
lowed by malignancy (39, 21.7%), organ transplantation (34,
18.9%), lung transplantation (25, 13.9%) and diabetes mellitus
(16, 9%).
Of 183 isolates, 108 (59%) were the S. apiospermum/
P. boydii phenotype and 75 (41%) were S. proliﬁcans (both
phenotypes recovered in six patients). The former was signif-
icantly associated with diabetes (p = 0.007), and S. proliﬁcans
was associated with haematologic cancer, cancer chemother-
apy and invasive scedosporiosis (p < 0.03). The number of
colonizations was 118 (65.6%) and the number of invasive
disease was 62 (34.4%).
The estimated annual incidence of invasive scedosporiosis
was one per million of the population [16]; underlying malig-
nancy (40%) and organ transplantation (29%) were common
within this group of invasive infections, although 11.3% had
no co-morbidity.
Independent predictors of invasive disease included stem
cell transplantation, leukaemia, neutropaenia (all p <0.001),
corticosteroid use (p 0.04) and diabetes (p 0.04). Scedospori-
um proliﬁcans lead to 33 (53.3%) and S. apiospermum/P. boydii
caused 29 (46.8%) cases of infection (not signiﬁcant); one
patient had infection with both. The main sites of infection
were lung (38.7%), blood (22.6%), skin/subcutaneous tissue
(14.5%), ear (14.5%), bone (12.9%) and sinuses (12.9%);
24.1% of patients had disseminated disease. Other affected
sites included the eye (n = 6) and brain (n = 3). Nine of 25
(36%) lung transplant patients from whom Scedosporium was
cultured had proven disease, with four having dissemination.
Crude 90-day mortality and clinician-judged attributable mor-
tality in patients with invasive disease were both 30.6%. Inde-
pendent predictors of death were S. proliﬁcans (48.5% vs.
10% for S. apiospermum/P. boydii phenotype; p 0.01) and
leukaemia (p 0.03).
Molecular identiﬁcation of 120 of the 183 isolates yielded
42 (35%) S. apiospermum, 29 (24.2%) S. aurantiacum and 49
(40.8%) S. proliﬁcans. The predicted prevalence of S. aurantia-
cum in the whole cohort (183 isolates) was ‡15.8%.
Characteristics associated with S. apiospermum and
S. aurantiacum are summarized in Table 1. Chronic lung dis-
ease was associated with isolation of S. aurantiacum
(p 0.008). Scedosporium aurantiacum, unlike S. apiospermum,
was not recovered from the brain or skin. Invasive disease
due to S. aurantiacum (n = 6) involved various body sites
(Table 1); these patients had diabetes (n = 3), solid tumours
(n = 1), chronic lung disease (n = 4) and autologous stem
cell transplants (n = 1); all were alive at 90 days of follow-up.
Forty-two of 54 (67.8%) patients treated with antifungal
drugs received voriconazole [single agent (n = 22), combined
with terbinaﬁne/liposomal amphotericin B (n = 20)]. Of
ﬁve antifungals tested, voriconazole was the most active
in vitro against all three Scedosporium species (Table 2). The
TABLE 1. Comparison of characteristics associated with
Scedosporium aurantiacum and Scedosporium apiospermuma
Characteristic
Scedosporium
aurantiacum
episodes (n = 29)
Scedosporium
apiospermum
episodes (n = 42)
Predisposing factor
Haematologic malignancy 1 (3.5) 3 (7.1)
Solid tumour malignancy 2 (6.9) 4 (9.5)
Lung transplantation 2 (6.9) 4 (9.5)
Diabetes 5 (17.2) 6 (14.3)
Chronic lung disease 15 (51.7)b 8 (19)
Cystic ﬁbrosis 1 (3.5) 2 (4.8)
Otherc 14 (48.3)b 6 (14.3)
Cancer chemotherapy 2 (6.9) 2 (4.8)
Corticosteroids 7 (24.1) 13 (31)
Disease status
Invasive disease 6 (20.7) 14 (33.3)
Body site of isolation
Sputum 8 (27.6) 7 (16.7)
Invasive disease 1 (3.4) –
Colonization 7 (24.1) 7 (16.7)
BAL 1 (3.4) 5 (11.9)
Invasive disease – 1
Colonization 1 (3.4) 4 (9.5)
Lung 1 (3.4) 4 (9.5)
Ear (swab/tissue) 5 (17.2) 10 (23.8)
Invasive disease 3 (10.3) 2 (4.8)
Colonization 2 (6.9) 8 (19)
Sinus tissue 3 (10.3) 4 (9.5)
Invasive disease 2(6.9) 1 (2.3)
Colonization 1 (3.4) 3 (7.1)
Skin/soft tissue – 8 (19)
Invasive disease – 3 (7.1)
Colonization – 5 (11.9)
Brain – 1 (2.3)
Bone 2 (6.9) 3 (7.1)
Eye 1 (3.5) 1 (2.3)
aData refer to the total numbers of episodes with isolates identiﬁed by molecu-
lar methods and represent n (%)total cases in each category.
bp 0.008 for ‘chronic lung disease’, p 0.004 for ‘other’. Comparisons are for
episodes of S. aurantiacum compared to S. apiospermum.
cChronic lung disease other than cystic ﬁbrosis.
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mimimum inhibitory concentrations (MICs) of all drugs were
similar for S. apiospermum and S. aurantiacum.
This nationwide survey of unselected patients is the
ﬁrst to deﬁne the clinical epidemiology and outcomes of
scedosporiosis on the basis of S. apiospermum, S. aurantiacum
and S. proliﬁcans. The results obtained highlight a substantial
prevalence of S. aurantiacum in Australia and suggest that it
causes infections similar to S. apiospermum.
As previously reported, immunocompromised patients
were at greatest risk of invasive scedosporiosis [2,9,11,12];
however, diabetes mellitus emerged as an independent risk
factor. Chronic lung disease, CF and lung transplantation did
not predict infection per se, but were risk factors for respira-
tory isolation of Scedosporium.
Scedosporium infections are reportedly uncommon post-
lung transplantation, although serious infections do occur
[17,18]. The rate of pulmonary scedosporiosis of 2.3% in
one study of lung/heart–lung recipients may represent an
overestimate because the data were based on cultures of
bronchoalveolar lavage ﬂuid/sputum [19]. In the present
study, proven (including disseminated) infection was diag-
nosed in 36% of lung recipients from whom Scedosporium
was recovered. Because the same S. apiospermum genotype
colonizing the airways prior to transplantation causes disease
post-transplantation [18], studies addressing the implications
of S. apiospermum colonization are warranted in this patient
group.
Key new ﬁndings obtained in the present study include
the recognition of S. aurantiacum as a medically important
species (‡15.8% isolates) and the observation that disease
manifestations and antifungal susceptibility proﬁles are similar
to those of S. apiospermum.
Only four clinical S. aurantiacum isolates have been
previously reported [6], whereas a single report indicated
that S. aurantiacum was less susceptible to antifungals than
S. apiospermum [20]. Scedosporium aurantiacum caused
malignant otitis externa, osteomyelitis, invasive sinusitis,
keratitis and pneumonia; however, no deaths resulted. This
benign outcome is interesting given recent data implicating
S. aurantiacum as the more virulent species within the P. boydii
complex [21].
The relatively low mortality (30.6%) in the present study
[2,9,11,12] may reﬂect differences in casemix or causative
species. Possibly, voriconazole therapy (in 68% patients)
impacted favourably on mortality, although we were unable
to compare outcomes by antifungal regimen as a result
of insufﬁcient patient numbers. Low voriconazole and
posaconazole MICs against S. aurantiacum suggest that these
agents may be effective for S. aurantiacum infections, but
further studies correlating MICs with in vivo outcomes are
required.
In conclusion, S. aurantiacum is an newly regognised
pathogen with similar epidemiological features and antifungal
susceptibilities to S. apiospermum. Further correlation of
epidemiology, therapies and outcomes is required to inform
evidence-based management guidelines.
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Scedosporium apiospermum AMB (26) 1–16 4.56 4 8
ITC (26) 0.125–2 0.65 0.5 2
VOR (26) 0.06–1.0 0.22 0.25 0.5
POS (20) 0.25–1.0 0.57 0.5 1
TRB (5) 32 32 32 32
Scedosporium aurantiacumd AMB (27) 2–16 7.42 8 16
ITC (27) 0.25–2 0.61 0.5 1
VOR (27) 0.03–0.5 0.20 0.25 0.25
POS (26) 0.125–1 0.43 0.5 0.5
Scedosporium proliﬁcans AMB (31) 0.5–>16 8.83 8 16
ITC (31) >16 16 >16 >16
VOR (31) 1–8 5.56 4 8
POS (26) >8 8 >8 >8
TRB (5) 1–4 4 2 4
AMB, amphotericin B; ITC, itraconazole; POS, posaconazole; TRB, terbinaﬁne; VOR, voriconazole.
aGM, geometric mean of the minimum inhibitory concentrations (MICs).
bMIC at which 50% of the isolates were inhibited.
cMIC at which 90% of the isolates were inhibited.
dSusceptibility to terbinaﬁne not determined for S. aurantiacum.
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Abstract
Rhinocerebral mucormycosis is a rare disease, affecting almost
exclusively patients with known predisposing conditions such as
diabetes mellitus, immunocompromised status, haemochromato-
sis or major trauma. Subsequent to a case of rhinocerebral
mucormycosis in a 78-year-old woman without any known risk
factor, we reviewed the published English-language literature and
found an additional 72 cases. Reviewing all the published case
series of mucormycosis involving any site, the proportion of
apparently normal hosts among cases of rhinocerebral muco-
rmycosis was found to be 9.06% (95% conﬁdence interval 6.7–
11.8). These ﬁndings suggest that rhinocerebral mucormycosis in
patients without known predisposing factors is more prevalent
than was previously believed.
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Rhinocerebral mucormycosis, the most common presentation
of mucormycosis [1–3] is limited, in most cases, to people
with previously recognized risk factors such as diabetes
mellitus, immunosuppression, iron overload or after trauma
[1,4,5]. Subsequent to a fatal case of rhinocerebral mucormy-
cosis in a patient without known predisposing factors, we
reviewed the English-language literature for cases in appar-
ently normal hosts. In addition, we searched for all case ser-
ies of mucormycosis to determine the relative proportion of
patients without previously recognized predisposing condi-
tions among patients with rhinocerebral mucormycosis.
Case Report
A 78-year-old woman presented to the emergency room with
left palate pain and somnolence. The patient’s medical history
was remarkable only for hypertension, treated with hydrochlo-
rothiazide. The white blood cell count was 19 400 cells/lL, with
92% neutrophils and the serum sodium level was 106 mmol/L.
A loose tooth seen in the left upper jaw was removed,
intravenous normal saline and amoxicillin/clavulanic acid was
started and the patient’s condition improved signiﬁcantly.
On the fourth hospital day, right eye chemosis, ptosis and
lateral gaze palsy with central retinal artery thrombosis
appeared, followed by disarthria and right hemiparesis.
Magnetic resonance imaging of the brain revealed pansinusitis
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